LILRB4 inhibits the expression of TRAF6 and downstream inflammatory factors, thereby inhibiting the occurrence and development of non-alcoholic fatty liver disease [33]. Here, LILRB4 is linked to metabolic dysfunction-associated steatotic liver disease.